Skip to content

Efficacy and safety of butylphthalide in the treatment of delayed encephalopathy caused by acute carbon monoxide poisoning/carbon monoxide poisoning: a multicenter, randomized, controlled clinical study

Efficacy and safety of butylphthalide in the treatment of delayed encephalopathy caused by acute carbon monoxide poisoning/carbon monoxide poisoning: a multicenter, randomized, controlled clinical study

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1900027779
Enrollment
Unknown
Registered
2019-11-28
Start date
2018-01-01
Completion date
Unknown
Last updated
2019-12-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute carbon monoxide poisoning / carbon monoxide poisoning delayed encephalopathy

Interventions

Experimental group:Treatment of delayed encephalopathy after acute carbon monoxide poisoning / carbon monoxide poisoning with butylphthalide
Control group:Conventional treatment

Sponsors

Baotou Central Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Outpatient or ward patients will voluntarily participate in the trial and sign the informed consent by themselves or their legal representatives; 2. Medium and severe diagnostic criteria in Diagnostic Criteria for Occupational Acute Carbon Monoxide Poisoning formulated by the Ministry of Health were met; 3. Aged 18 to 80 years; 4. The course of disease was less than 48 hours from onset to admission; 5. Glasgow Coma Scale 3 to 12 points.

Exclusion criteria

Exclusion criteria: 1. Acute cerebrovascular disease and encephalopathy caused by other causes; 2. Mixed poisoning patients; 3. Past dementia or mental disorders; 4. Burns or injuries; 5. Severe diseases of heart, lung, liver, kidney, blood system and hematopoietic system; 6. Gastrointestinal diseases or gastrointestinal surgery may affect gastrointestinal absorption. 7. Serious infection uncontrolled; 8. Breast-feeding or pregnancy; 9. Anyone who has allergic history to celery or Enbipu in the past; 10. Patients with malignant tumors or undergoing antineoplastic therapy; 11. Butylphthalide was taken within 3 months prior to the date of informed consent; 12. Researchers think that it is not suitable for patients to participate in this clinical study.

Design outcomes

Primary

MeasureTime frame
Mini Mental State Examination(MMSE);

Secondary

MeasureTime frame
daily living ability scale (BI score);European Five-Dimensional Health Scale (EQ-5D);

Countries

China

Contacts

Public Contactzhang Jingfen

Baotou Central Hospital

1846224761@qq.com+86 13947253466

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026